Stock Events

Stock Events

MiNK Therapeutics 

$10.85
0
+$0.2+1.88% Today

Statistics

Day High
10.85
Day Low
10.02
52W High
-
52W Low
-
Volume
1,867
Avg. Volume
-
Mkt Cap
50.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Next
-0.86
-0.79
-0.72
-0.65
Expected EPS
-0.78
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-21.57MNet Income

Analyst Ratings

$35.00Average Price Target
The highest estimate is 35.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INKT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap141.84M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, including NK cell-based therapies, making it a direct competitor in the cell therapy market.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Kite Pharma, has a strong presence in the cell therapy space for oncology, competing with MiNK's approach to cancer treatment.
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, competing in the broader cell therapy market for cancer, which includes MiNK's NK cell therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR T-cell therapies, competing in the innovative cancer treatment space with MiNK.
NovoCure
NVCR
Mkt Cap1.2B
NovoCure operates in the oncology space with a novel tumor treating fields (TTF) technology, offering a different approach to cancer treatment but still competing for the same patient population as MiNK.

About

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Show more...
CEO
ISIN
US6036932019

Listings

F
DE
6Q40.F
XNAS
US
INKT
BOATS
BOATS
INKT.BOATS

0 Comments

Share your thoughts

FAQ

What is MiNK Therapeutics stock price today?▼
The current price of INKT.BOATS is $10.85 USD — it has increased by +1.88% in the past 24 hours. Watch MiNK Therapeutics stock price performance more closely on the chart.
What is MiNK Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MiNK Therapeutics stocks are traded under the ticker INKT.BOATS.
What is MiNK Therapeutics market cap?▼
Today MiNK Therapeutics has the market capitalization of 50.93M
When is the next MiNK Therapeutics earnings date?▼
MiNK Therapeutics is going to release the next earnings report on May 13, 2026.
What were MiNK Therapeutics earnings last quarter?▼
INKT.BOATS earnings for the last quarter are -0.65 USD per share, whereas the estimation was -0.86 USD resulting in a +23.98% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MiNK Therapeutics revenue for the last year?▼
MiNK Therapeutics revenue for the last year amounts to 0 USD.
What is MiNK Therapeutics net income for the last year?▼
INKT.BOATS net income for the last year is -21.57M USD.
When did MiNK Therapeutics complete a stock split?▼
MiNK Therapeutics has not had any recent stock splits.